

Gilead Sciences Slovenia EFPIA Report 2021

	Full name	Principal Practice Address or Registered Seat of Institution	Donations and Grants to HCOs (Art. 3.1.1.1)	Contribution to costs of Events (Art. 3.1.1.2 & 3.1.2.1)			Fee for service and consultancy (Art 3.1.1.3 & 3.1.2.2)		TOTAL (OPTIONAL)
				Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)								
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons								
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.2						7,228.00 €		7,228.00 €
	Number of Recipients (named list, where appropriate) - Art. 3.2						5		5
% of total transfers of value to individual HCPs - Art. 3.2						100%			
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)								
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons								
	Aggregate amount attributable to transfers of value to such Recipients - Art. 3.2								
	Number of Recipients included in the aggregate disclosure - Art. 3.2								
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.2									
R&D	AGGREGATE DISCLOSURE								
	Transfers of Value re Research & Development as defined (Art. 3.4)								